March 7, 2022
Tollys and Gustave Roussy enter into new research agreement
Tollys has entered into a sponsored research agreement with Gustave Roussy.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 6, 2022
Oncimmune Holdings in new commercial contract with 10 companies
Oncimmune Holdings has signed a commercial contract with a new top 10 global pharmaceutical company by revenue, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (“CIDP”).
March 3, 2022
Medix Biochemica Launches New Website Establishing it as the Ultimate IVD Raw Materials Supplier
Medix Biochemica has announced the launch of its refreshed and expanding brand to reflect both the exciting improvements to its offering…
March 3, 2022
Pfizer’s RSV Vaccine Candidate Receives Breakthrough Therapy Designation for US
Pfizer has announced that its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, received Breakthrough Therapy Designation from the…
March 3, 2022
Roche Announces Donation of Essential Medicines to Ukraine
Roche have announced an initial donation of essential medicines to Ukraine, after the country has been violently invaded by Russia.…
March 2, 2022
MiGenTra Announces Formation of International Advisory Board
MiGenTra, headquartered in Berlin, Germany and MiGenTra Egypt, located with its ‘Facility of the Future’ in Cairo, Egypt, have announced…
March 2, 2022
Accure Therapeutics Licences Neuroprotective Drug Candidate to Ophthalmology Company Oculis
Oculis and Accure Therapeutics have announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a…
March 2, 2022
Holographyx Announces U.S. and European Patent for Anti-Counterfeiting System for Blister-Packs
Holographyx has been granted a U.S. patent for its Holo-Blister product along with a European Patent for the development of…
March 2, 2022
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, has…
March 1, 2022
AbbVie Acquires V-Bio Ventures’s Portfolio Company Syndesi Therapeutics
V-Bio Ventures has announced the completion the acquisition of its portfolio company Syndesi Therapeutics SA by AbbVie (NYSE: ABBV), which…